AstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win
Sone-Ve cut the risk of death by 42% in a Phase III gastric cancer trial; median survival was 10.6 months versus 6.4
We haven't written up this one. Quartz has the full story — the link below goes straight to it.